Currently, tissue plasminogen activator (tPA), a thrombolytic agent to restore blood flow, is the only drug used in the clinical treatment of stroke approved by FDA, but only 10% of patients meet the standard for using tPA as a therapeutic drug for stroke (Fugate and Rabinstein, 2014). Here, PLAT is linked to stroke disorder.